Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has received approval from the U.S. Food and Drug Administration to begin clinical trials of its Class 1 innovative drug SYH2072, a highly selective aldosterone synthase inhibitor tablet for uncontrolled and resistant hypertension, complementing an earlier clinical trial approval obtained in China. Backed by positive pre-clinical data, favorable safety and pharmacokinetic profiles, and multiple patent applications filed domestically and abroad, the candidate is positioned as a potential best-in-class therapy addressing significant unmet clinical needs in difficult-to-treat hypertension, strengthening CSPC’s innovation credentials and international R&D footprint in cardiovascular medicine.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company engaged in the research, development and manufacture of innovative drugs, with a growing portfolio of Class 1 new chemical entities targeting major therapeutic areas such as cardiovascular and metabolic diseases in both Chinese and international markets.
Average Trading Volume: 128,098,872
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$105.6B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.